The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
Introduction: AZD9977 is a novel mineralocorticoid receptor (MR) modulator, which in preclinical studies demonstrated organ protection without affecting aldosterone-regulated urinary electrolyte excretion. However, when tested in humans, using fludrocortisone as an MR agonist, AZD9977 exhibited simi...
Main Authors: | Krister Bamberg, Lena William-Olsson, Ulrika Johansson, Rasmus Jansson-Löfmark, Judith Hartleib-Geschwindner |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi - SAGE Publishing
2019-02-01
|
Series: | Journal of the Renin-Angiotensin-Aldosterone System |
Online Access: | https://doi.org/10.1177/1470320319827449 |
Similar Items
-
Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
by: Krister Bamberg, et al.
Published: (2018-01-01) -
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
by: Andrew Whittaker, et al.
Published: (2020-03-01) -
Effects of the mineralocorticoid fludrocortisone on fibrinolytic function in healthy subjects
by: Katja Lottermoser, et al.
Published: (2000-12-01) -
Aldosterone and Mineralocorticoid Receptors—Physiology and Pathophysiology
by: John W. Funder
Published: (2017-05-01) -
Pathophysiological Roles of Aldosterone and Mineralocorticoid Receptor in the Kidney
by: Kazi Rafiq, et al.
Published: (2011-01-01)